Zobrazeno 1 - 10
of 72
pro vyhledávání: '"W, Robeson"'
Autor:
Kristin Graf, Meggan Mackay, Thomas Chaly, Vijay Dhawan, David Eidelberg, Limei Zhuo, Matthew Hellman, David Bjelke, W. Robeson
Publikováno v:
Journal of Nuclear Medicine. 56:869-872
UNLABELLED (11)C-CNS5161 (N-(2-chloro-5-methylthiophenyl)-N'-(3-methylthiophenyl)-N'-(11)C-methylguanidine) has been successfully used in PET imaging of N-methyl-d-aspartate (NMDA) receptors. However, no human dosimetry data have been published. We a
Publikováno v:
IEEE Transactions on Nuclear Science. 40:135-142
In positron-emission tomography (PET), to certify that the observed radioactivity in the organ of interest represents the true underlying radioactivity concentration, an experimental/theoretical treatment of factors such as scatter, randoms, reconstr
Autor:
L.F. Mausner, George E. Meinken, Italo Zanzi, Suresh C. Srivastava, D. Margouleff, W. Robeson, J Markowitz
Publikováno v:
Nuclear Medicine Communications. 13:76-81
There is no consensus or a uniform technique for measuring gastric emptying and numerous modalities have been reported. We report here the results obtained using a modification of the published techniques for the simultaneous measurement of duodenoga
Autor:
V, Dhawan, A, Belakhlef, W, Robeson, T, Ishikawa, C, Margouleff, S, Takikawa, T, Chaly, K, Kazumata, D, Margouleff, D, Eidelberg
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 37(11)
PET, in conjunction with 18F-fluorodopa (FDOPA), has become the standard technique to assess basal ganglia degeneration in patients with movement disorders. Based on published dosimetry data, the injected dose of FDOPA is limited to 111 Mbq (3 mCi) b
Autor:
W, Robeson, D, Margouleff
Publikováno v:
Clinical nuclear medicine. 21(3)
Autor:
D, Eidelberg, J R, Moeller, T, Ishikawa, V, Dhawan, P, Spetsieris, T, Chaly, W, Robeson, J R, Dahl, D, Margouleff
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 36(3)
Fluorine-18-fluorodeoxyglucose (FDG) and PET have been used to identify an abnormal regional metabolic covariance pattern in Parkinson's disease (PD). To examine the potential use of this covariance pattern as a metabolic imaging marker for PD, we de
Publikováno v:
Journal of Vascular and Interventional Radiology. 23:S124
Autor:
Phoebe G. Spetsieris, S. Takikawa, D. Margouleff, David Eidelberg, W. Robeson, Italo Zanzi, Dibyendu Bandyopadhyay, Robert Dahl, Thomas Chaly, Vijay Dhawan
Publikováno v:
Physics in medicine and biology. 39(9)
Positron emission tomography (PET) measurements of cerebral glucose utilization using 18F-fluorodeoxyglucose (FDG) are a useful tool in the investigation of localized brain function in normal and disease states. A major impediment to the application
Autor:
S, Takikawa, V, Dhawan, T, Chaly, W, Robeson, R, Dahl, I, Zanzi, F, Mandel, P, Spetsieris, D, Eidelberg
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 35(6)
PET has been used to quantify striatal 6-[18F]fluoro-L-dopa (FDOPA) uptake as a measure of presynaptic dopaminergic function. Striatal FDOPA uptake rate constants (Ki) can be calculated using dynamic PET imaging with measurements of the plasma FDOPA
Autor:
I, Zanzi, J, Markowitz, S C, Srivastava, W, Robeson, L F, Mausner, G E, Meinken, D, Margouleff
Publikováno v:
Nuclear medicine communications. 13(2)
There is no consensus or a uniform technique for measuring gastric emptying and numerous modalities have been reported. We report here the results obtained using a modification of the published techniques for the simultaneous measurement of duodenoga